On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) and XBRYK™ (denosumab-dssb; 120 mg vial), referencing Amgen’s PROLIA® and XGEVA®,...more
2/18/2025
/ Biosimilars ,
Compliance ,
Department of Health and Human Services (HHS) ,
European Commission ,
Food and Drug Administration (FDA) ,
Life Sciences ,
New Regulations ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs ,
Regulatory Requirements